With product patents set to kick in by 2005, the few big multinational drug companies that had kept India out of their plans are having a change of heart. To begin with, Bristol-Myers Squibb, the......
Bristol-Myers Squibb India, the wholly owned subsidiary of the $19.2 billion US pharmaceutical company, has launched Baraclude, its anti-Hepatitis B drug in India.Baraclude, an entecavir oral......
Aurobindo Pharma has received licences from Bristol Myers Squibb Co to market two anti-AIDS drugs in 49 countries. The licences are for Stavudine and Didanosine, Aurobindo said.The licence allows......
Could this finally be the end for Bristol-Myers Squibb Chief Executive Peter Dolan? A board meeting Tuesday, Sept. 12 could determine Dolan's fate. He is under fire because of a failed attempt to......
Dinesh Thakur, the whistle-blower who put Ranbaxy in the dock, was heading the company's information technology division for research and development (R&D) until eight years ago.Thakur, a Bachelor......